CD70 EXPRESSION IN ENDOMETRIAL ENDOMETRIOID CARCINOMA: AN IMMUNOHISTOCHEMICAL STUDY

  • Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt.
  • Department of Pathology, Faculty of Medicine, Fayoum University, Fayoum.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Aim: CD70 is aberrantly upregulated in hematological malignancies and some solid malignancies, including renal cell carcinoma (RCC), brain tumors, thymic carcinoma, melanoma, pancreatic, nasopharyngeal, lung, ovarian and colon carcinoma. CD70 on tumor cells interacts with its receptor CD27 on tumor infiltrating lymphocytes (TILs), inducing apoptosis of B and T lymphocytes resulting in immune suppression. CD70 expression has been linked to poor prognostic factors and progression in many tumors. Novel therapeutic agents targeting CD70 have entered clinical trials. To our knowledge, CD70 expression was not assessed in endometrial endometrioid carcinoma (EEC). The purpose of our study was to characterize CD70 expression in EEC specimens and correlate its expression with other pathological prognostic variables. Methods: This study has included 60 paraffin-embedded EEC. The tumors were categorized by grade, stage, depth of myometrial invasion by the tumor tissue, the presence of lympho-vascular emboli, regional lymph node metastasis and TILs within the vicinity of the tumor. A histochemical score was used to evaluate CD70 expression by the tumor cells. Results: In this study, CD70 showed mild expression in 16 cases (26.7%), moderate expression in 20 cases (33.3%), marked expression in 12 cases (20%), while it is negative in 12 cases (20%). CD70 expression showed no significant relation with tumor grade (P>0.05). CD70 expression was significantly more marked in tumors of higher stage as well as in tumors infiltrating more than half the myometrial thickness (P<0.05). CD70 expression was significantly higher in tumors having lympho-vascular emboli and in tumors with metastatic regional lymph nodes (P<0.05). Also, there was significant positive correlation between CD70 expression and the density of TILs (P<0.05). Conclusion: CD70 expression in EEC is significantly higher in tumors having poor prognostic factors including stage, depth of myometrial invasion, lympho-vascular emboli, regional lymph node metastasis. CD70 expression also showed significant positive correlation with TILs. These findings suggest that CD70 might be a good targeted therapy in endometrioid carcinoma. Further researches are warranted to clarify the function of CD70 expression in the pathophysiology of EEC, to elucidate the response to treatment with CD70 targeted therapy and the possibility of using CD70 as a predictive immunohistochemical marker for assessing the response to anti-CD70 targeted therapy.

  1. Akiba H, Miyahira Y, Atsuta M, et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med. 2000. 191:375?80.
  2. AminMB, Greene FL, Edge SB, Compton CC, GershenwaldJE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more ?personalized? approach to cancer staging. CA: A cancer journal for clinicians. 2017; 67(2): 93-99.
  3. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. CurrOpinImmunol. 2005. 17:275?281.
  4. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003. 3:609-20.
  5. De Meulenaere A,?Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P, Duprez F, Ferdinande L. Rottey S. CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck. 2016, 83:327-333.
  6. Doll A, Abal M and Rigau M, Monge M, Gonzalez M,Demajo S, Col?s E, Llaurad? M, et al. Novel molecular profiles of endometrial cancer-new light through old windows. The Journal of Steroid Biochemistry and Molecular Biology. 2008; 108(3-5): 221-229.
  7. ElMouallem N, Smith SC, Paul Sarcomatoid renal cell carcinoma: Biology and treatment advances. Urologic Oncology: Seminars and Original Investigations. 2018; 36 (6): 265-271.
  8. FerlayJ, Soerjomataram?I, Dikshit?R, Eser?S, Mathers?C, Rebelo?M, Parkin?DM, Forman?D, BrayCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136 (5): 359-386.
  9. GeH, Mu?L, Jin?L, Yang?C, Chang?YE, Long?Y, DeLeon G, Deleyrolle?L, Mitchell DA, Kubilis?PS, Lu?D, Qi J, Gu?Y, Lin?Z, Huang Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM. International Journal of Cancer. 2017; 141 (7): 1434-1444.
  10. Hammond MEH, Hayes DF, Dowsett M, Allred D, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer.? Archives of Pathology & Laboratory Medicine. 2010; 134 (7): 48-72.
  11. Hintzen RQ, Lens SM, Koopman G, et al. CD70 represents the human ligand for CD27. Int Immunol. 1994. 6:477?80.
  12. Hishima T, Fukayama M, Hayashi Y, et al. CD70 expression in thymic carcinoma. American Journal of Surgical Pathology. 2000. 24:742-746.
  13. Jacobs J, Zwaenepoel K, Rolfo C, Van den?Bossche J, Deben C, Silence K, Hermans C, Smits E, Schil PV, Lardon F, Deschoolmeester V, and Pauwels P. Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. Oncotarget. 2015; 6 (15): 13462-13475.
  14. Jacobs J,?Deschoolmeester V,?Zwaenepoel K,?Rolfo C,?Lardon F,?Smits E?and?Pauwels P. Cisplatin and anti-CD70 therapy: Ideal partners in crime against NSCLC. Cancer Research. 2016; 76 (14), 4981.
  15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011; 61 (2): 69-90.
  16. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010. 60: 277-300.
  17. Jilaveanu LB,Sznol J,?Aziz SA,?Duchen D,?Kluger HM,?and?CampCD70 Expression Patterns in Renal Cell Carcinoma. Hum Pathol. 2012; 43(9): 1394-1399.
  18. Junker K, Hindermann W, von Eggeling F, Diegmann J, Schubert J. CD70 - A new tumor specific biomarker for renal cell carcinoma. Journal of Urology. 2005; 173 (6): 2150-2153.
  19. Kandoth C, Schultz N, Cherniack AD, Akbani R, Kucherlapati R, Mardis ER, Levine DA, Ayala B, Chu?AL, Jensen MA, Kothiyal P, Pihl TD, Pontius J. Integrated genomic characterization of endometrial carcinoma.2013. Nature, 497:67-73.
  20. Lens SM, Drillenburg P, den Drijver BF, et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol. 1999. 106:491-503.
  21. Lens SM, Tesselaar K, van Oers MH, et al. Control of lymphocyte function through CD27-CD70 interactions. SeminImmunol. 1998. 10:491-9.
  22. Nilsson A, de Milito A, Mowafi F, Winberg G, Bjork O, Wolpert EZ, Chiodi F. Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. ExpHematol. 2005. 33: 1500-1507.
  23. Park YP, Jin L, Bennett KB, Fredenburg KM, Tseng JE, Wang D, Chan EKL, Chang LJ and Huang J. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma. Oral Pathology. 2018. 78, 145-150.
  24. Pich C, Sarrabayrouse G, Teiti I, Mariam? B, Rochaix P, Lamant L, Favre G, Maisongrosse V, Tilkin-Mariam? AF. Melanoma-expressed CD70 is involved in invasion and metastasis. 2016.British Journal of Cancer, 114, 63?70.
  25. Ryan MC, Kostner H, Gordon KA, Duniho S,?Sutherland MK,?Yu C, Kim KM, Nesterova A, Anderson M, McEarchern JA, Law CL, Smith Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody?drug conjugate SGN-75. British Journal of Cancer. 2010. 103. 676-684.
  26. Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SME, Saunders M,Wajant H, Brouckaert P,Huyghe L,Hauwermeiren TV, Alain ThibaultA, De Haard ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs. 2014, 6:523-532.
  27. Thangaraju S, Subramani E, Chakravarty B, Chaudhury Therapeutic targeting of the TNF superfamily: A promising treatment for advanced endometrial adenocarcinoma. Gynecologic Oncology. 2012; 127 (2): 426-432.
  28. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A.Global cancer statistics, 2012.CA Cancer J Clin. 2015; 65(2): 87-108.
  29. Tsunekazu H, Masashi F, Yukiko H, Takeshi F, Takayo, Nobuaki F, Morio K. CD70?Expression in?Thymic Carcinoma. The American Journal of Surgical Pathology. 2000; 24(5), 742-746.
  30. van Oosterwijk MF, Juwana H, Arens R, et al. CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. Int Immunol. 2007. 19:713?718.
  31. Wischhusen J, Jung G, Radovanovic I, et al. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Research. 2002. 62:2592-2599.
  32. YEngT, Fuller CD, Jagirdar J, Bains Y, ThomasJr CR. Thymic carcinoma: state of the art review.International Journal of Radiation Oncology, Biology, Physics. 2004; 59(3), 654-664.
  33. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013, 19: 2240-2247.

[Dina F. El Yasergy, Moustafa A. Abousarie and Lobna O. Abdel Salam (2019); CD70 EXPRESSION IN ENDOMETRIAL ENDOMETRIOID CARCINOMA: AN IMMUNOHISTOCHEMICAL STUDY Int. J. of Adv. Res. 7 (Apr). 815-824] (ISSN 2320-5407). www.journalijar.com

Dina Fawzy El-Yasergy
El-Yasergy D

DOI:

Article DOI: 10.21474/IJAR01/8890      
DOI URL: https://dx.doi.org/10.21474/IJAR01/8890

Download Full Paper

Download PDF No. of Downloads: 16 | No. of Views: 86